Abstract：Objective To investigate the therapeutic effect of Shenmai Injection on acute cerebral infarction. Methods Retrospective analysis was performed on the clinical data of 122 patients with acute cerebral infarction who were treated in the first area of the Department of Encephalopathy, Dongzhimen Hospital, Beijing University of Chinese Medicine from June 2017 to June 2019. According to the treatment methods, the patients were divided into treatment group (66 cases) and control group (56 cases). Both groups were given conventional treatment such as antiplatelet, lipid-lowering, hypotensive, and glycemic control, while the treatment group was given intravenous infusion of Shenmai Injection on the basis of conventional treatment. The control group was given Danhong Injection intravenously, and both groups were treated for 14 days. National Institutes of health stroke scale (NIHSS) scores and the incidence of adverse events were compared between the two groups before and after 14 days of treatment. Results After 14 days of treatment, the NIHSS scores in both groups were lower than that before treatment, and the treatment group were lower than the control group, with statistical significance (P ＜ 0.05). There was no significant difference in unknown etiology (UE) subtype NIHSS scores between the two groups before and after treatment (P ＞ 0.05). After 14 days of treatment, NIHSS scores of cardioembolism (CS), large-artery atherosclerosis (LAA), penetrating artery disease (PAD) and other etiology (OE) subtypes in both groups were lower than those before treatment, and the differences were statistically significant (P ＜ 0.05). The NIHSS score of LAA subtype in the treatment group was lower than that in the control group, and the difference was statistically significant (P < 0.05). There was no significant difference in the NIHSS scores of CS, PAD, OE and UE subtypes between the two groups (P ＞ 0.05). No obvious adverse reactions were found in both groups during the treatment. Conclusion Shenmai Injection can effectively improve the degree of neurological impairment in patients with acute cerebral infarction, and its effect on LAA subtype cerebral infarction is obviously better than that of Danhong Injection, and its effect is similar to that of Danhong Injection in other subtypes.
京公网安备 11010502046598号